Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2026
Serum apoptosis inhibitor of macrophage is associated with radiologic severity in pulmonary Mycobacterium avium complex disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kajiwara Chiaki, Urabe Naohisa, Shiozawa Ayako, Yamaguchi Tetsuo, Tateda Kazuhiro
Аннотация
BACKGROUND: Pulmonary Mycobacterium avium complex disease (MAC-PD) is a chronic infection with variable severity and treatment responses. It lacks blood biomarkers that reflect disease burden and early treatment-related biological activity. We evaluated whether serum apoptosis inhibitor of macrophage (AIM), a macrophage-derived soluble protein, is associated with radiologic severity and changes during treatment in MAC-PD.
METHODS: This prospective observational pilot study included 18 female patients with MAC-PD who received guideline-based therapy for at least 6 months. Serum AIM levels were measured at baseline and 6 months. Radiologic severity and symptom burden were assessed using Nodules-Infiltration-Cavities-Ectasis (NICE) score and Chronic Obstructive Pulmonary Disease Assessment Test (CAT), respectively. C-reactive protein, Krebs von den Lungen-6, surfactant protein D, and albumin levels were analyzed as comparator markers.
RESULTS: Serum AIM was associated with the NICE score at baseline (Spearman's ρ = 0.648, 95% CI 0.260-0.856, p = 0.004) and after 6 months (ρ = 0.701, 95% CI 0.348-0.880, p = 0.001). AIM levels decreased after treatment (median, 420.1-331.7 ng/mL; p = 0.015). NICE scores decreased (median, 9-8; p = 0.077), but the change did not reach statistical significance. CAT scores decreased (median, 11-6; p = 0.007). The percentage change in AIM was not significantly associated with absolute changes in CAT or NICE scores.
CONCLUSIONS: Serum AIM was associated with radiologic disease burden in patients with MAC-PD at baseline and 6 months and decreased during the first 6 months of GBT. Larger studies are needed to further evaluate its clinical utility.
METHODS: This prospective observational pilot study included 18 female patients with MAC-PD who received guideline-based therapy for at least 6 months. Serum AIM levels were measured at baseline and 6 months. Radiologic severity and symptom burden were assessed using Nodules-Infiltration-Cavities-Ectasis (NICE) score and Chronic Obstructive Pulmonary Disease Assessment Test (CAT), respectively. C-reactive protein, Krebs von den Lungen-6, surfactant protein D, and albumin levels were analyzed as comparator markers.
RESULTS: Serum AIM was associated with the NICE score at baseline (Spearman's ρ = 0.648, 95% CI 0.260-0.856, p = 0.004) and after 6 months (ρ = 0.701, 95% CI 0.348-0.880, p = 0.001). AIM levels decreased after treatment (median, 420.1-331.7 ng/mL; p = 0.015). NICE scores decreased (median, 9-8; p = 0.077), but the change did not reach statistical significance. CAT scores decreased (median, 11-6; p = 0.007). The percentage change in AIM was not significantly associated with absolute changes in CAT or NICE scores.
CONCLUSIONS: Serum AIM was associated with radiologic disease burden in patients with MAC-PD at baseline and 6 months and decreased during the first 6 months of GBT. Larger studies are needed to further evaluate its clinical utility.